June 17, 2020 / 12:54 PM / 2 months ago

BRIEF-Atara Biotherapeutics Says First Patient Enrolled In Randomized Placebo-Controlled Study Of Allogeneic T-Cell Therapy ATA188

June 17 (Reuters) - Atara Biotherapeutics Inc:

* ATARA BIOTHERAPEUTICS ANNOUNCES FIRST PATIENT ENROLLED IN RANDOMIZED PLACEBO-CONTROLLED STUDY OF ALLOGENEIC T-CELL THERAPY ATA188 IN PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below